Posaconazole IV solution + Posaconazole powder for oral suspension

Phase 1Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Neutropenia

Conditions

Neutropenia

Trial Timeline

Sep 7, 2015 → Sep 3, 2018

NCT ID

NCT02452034

About Posaconazole IV solution + Posaconazole powder for oral suspension

Posaconazole IV solution + Posaconazole powder for oral suspension is a phase 1 stage product being developed by Merck for Neutropenia. The current trial status is completed. This product is registered under clinical trial identifier NCT02452034. Target conditions include Neutropenia.

What happened to similar drugs?

8 of 18 similar drugs in Neutropenia were approved

Approved (8) Terminated (5) Active (8)

✅MicafunginAstellas PharmaApproved

❌HHPG-19K InjectionJiangsu Hengrui MedicinePhase 3

✅Imipenem + ImipenemMerckApproved

✅Ceftolozane-Tazobactam + MeropenemMerckApproved

✅Ceftolozane-tazobactam IVMerckApproved

❌Daptomycin + DaptomycinMerckPhase 3

🔄pegfilgrastimAmgenPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02452034	Phase 1	Completed	Sep 7, 2015	Sep 3, 2018	Neutropenia

Competing Products

20 competing products in Neutropenia

See all competitors

Product	Company	Stage	Hype Score
Micafungin	Astellas Pharma	Approved	39
pegfilgrastim	Kyowa Kirin	Phase 2	35
HHPG-19K Injection	Jiangsu Hengrui Medicine	Phase 3	32
caspofungin acetate + Comparator: AmBisome	Merck	Phase 2	35
Imipenem + Imipenem	Merck	Approved	43
Ceftolozane-Tazobactam + Meropenem	Merck	Approved	50
Ceftolozane-tazobactam IV	Merck	Approved	35
Daptomycin + Daptomycin	Merck	Phase 3	32
pegfilgrastim	Amgen	Phase 3	40
Neulasta (pegfilgrastim)	Amgen	Approved	43
Liposomal amphotericin B (AmBisome®) + Liposomal amphotericin B (AmBisome®)	Gilead Sciences	Approved	35
Filgrastim Hospira (US) + US-approved Neupogen®	Pfizer	Phase 1	29
HSP-130 + US-approved Neulasta + EU-approved Neulasta	Pfizer	Phase 1	29
linezolid + vancomycin	Pfizer	Phase 3	40
Anidulafungin	Pfizer	Phase 1/2	32
Nivestim®	Pfizer	Pre-clinical	18
Antibacterial agent for the treatment of febrile neutropenia	Pfizer	Pre-clinical	26
Voriconazole	Pfizer	Phase 1/2	32
Filgrastim Hospira (US) + U.S.-approved Neupogen®	Pfizer	Phase 1	29
ciprofloxacin + cefepime	Bayer	Phase 3	37